Brain Scans Reveal Psilocybin Produces Dream-Like Neural Patterns
Researchers studying the psychoactive compound in magic mushrooms discovered that the human brain under the influence of psilocybin exhibits activity patterns remarkably similar to those observed during dreaming. The findings, published in the journal Human Brain Mapping, offer one of the first physical explanations for why psychedelic experiences are frequently described as dreamlike.
The study was led by Dr. Enzo Tagliazucchi at Germany’s Goethe University. The research team analyzed brain imaging data from 15 volunteers who received intravenous psilocybin while inside a functional magnetic resonance imaging (fMRI) scanner. Each participant was scanned under both psilocybin and a placebo for comparison.
Heightened Activity in Primitive Brain Networks
The researchers tracked fluctuations in the blood-oxygen level dependent (BOLD) signal, which measures activity levels across different brain regions. Under the influence of psilocybin, activity in the brain’s more primitive network — the one associated with emotional processing — became significantly more pronounced.
Several regions within this network, including the hippocampus and the anterior cingulate cortex, fired simultaneously. This synchronized activation pattern closely mirrors what occurs during REM sleep, the phase most strongly associated with vivid dreaming.
Disrupted Higher-Order Thinking
At the same time, the brain network responsible for higher-level cognitive functions, including self-awareness and structured thought, became more disjointed and uncoordinated. This dual effect — amplified emotional processing coupled with diminished executive control — may account for the sensation of expanded consciousness that psilocybin users commonly report.
Robin Carhart-Harris of Imperial College London’s department of medicine, a collaborator on the study, noted the significance of seeing similarities between psychedelic brain activity and dream sleep patterns, particularly given that both states engage primitive brain areas linked to emotion and memory.
Therapeutic Potential Under Investigation
The research exists within a broader context of renewed scientific interest in psychedelic compounds for medical applications. At the time of the study, British researchers were exploring whether psilocybin could alleviate severe treatment-resistant depression, with early-stage experiments yielding encouraging results.
In parallel, U.S. researchers had observed positive outcomes in clinical trials using MDMA to treat post-traumatic stress disorder. These efforts collectively represent a shift toward rigorous investigation of substances long relegated to the margins of pharmacological research.
Ancient Use Meets Modern Neuroscience
Magic mushrooms grow naturally on every inhabited continent and have been used for thousands of years in religious and ceremonial contexts. The modern neuroscience approach to understanding these substances involves deliberately perturbing normal brain function to observe what changes. As Tagliazucchi explained, psychedelic drugs are powerful tools for exploring what happens in the brain when consciousness is profoundly altered — precisely because they produce such marked and novel disruptions to ordinary cognition.
